(PharmaNewsWire.Com, May 17, 2017 ) The Asia-Pacific Multiple Myeloma Therapeutics Market research report, published by Market Data Forecast estimates that the market itself was worth $1.37 billion in 2016 and expected to grow at a CAGR of 5.5%, to reach $1.79 billion by 2021 with a cumulative growth rate of $0.42 billion in the span of five years.
Multiple Myeloma is a rare form of cancer caused due to malignant plasma cells. When plasma cells become cancerous, they produce a tumor called plasmacytoma. If someone has more than one plasmacytoma, they have multiple myeloma. This is essentially a treatable cancer. DNA alterations, Stem cell transplants, Radiation therapy and surgeries are the available treatment options for multiple myeloma. The other factors which can have a significant impact on multiple myeloma treatment are age and general health, results of laboratory and cytogenetic (genomic) tests, symptoms and disease complications, prior myeloma treatment, patient’s lifestyle, goals, views on quality of life, and personal preferences
The report also presents detailed analysis of multitude of factors affecting the endoscopy devices market bearing either positive or negative outcomes. Some of those factors are: • Rise in geriatric population • Development of novel therapeutics and evolving multiple myeloma therapies • Improving Clinical outcomes through all stages of the disease • High cost associated with the treatment of this disease
For granular level understanding the Multiple Myeloma Therapeutics Market is segmented based on product and application, each being provided with Market Size Estimates and Y-o-Y Forecasts. The Asia-Pacific Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)).
Due to increase in geriatric population in the countries like China and India, Asia-Pacific is expected to witness highest growth rate in the forecast period. Based on geography the market is analyzed under various regions namely, China, India, Japan, South Korea and Australia. Australia and Japan are most likely to increase in the forecast period due to rising number of myeloma cases in the region.
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, Redhill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc. and Johnson and Johnson.
The Asia-Pacific Water Endoscopic Devices Market report offers wide-range of scope:
• Regional and country-level analysis that provides an individual perspective of Asia-Pacific region and the aforementioned countries
• Know more about key areas of industry growth via detailed Segment-level analysis on basis of product type long with market size forecasts and y-o-y estimations
• Detailed explanation of major drivers, restraints, opportunities, and challenges (DROC) that affect the market and impact the ever-shifting market dynamics
• Strategic Analyses containing PESTLE and Porter’s Five Forces Analyses which are obtained by studying the macro & micro environmental factors that affect the market demographics
• Comprehensive listing of key market players along with Company overview, product portfolios, financials (subjected to availability), SWOT analysis and analyst overview
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• Market Outlook - Investment opportunities devised by stand in experts to provide both individuals and organizations a strong financial foothold in the market
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
